Active	Status	Sponsor type	Region	Phase	Filter
6 Active 2 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Symeonidis, Argiris
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Initiation of new trial in Ph+ ALL Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL	Active, not recruiting	3	245	Europe, Canada, Japan, US, RoW	Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone	Takeda	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	08/22	07/27
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial) Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial) Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial) Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial) Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial) Jul 2023 - Dec 2023: Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Dec 2023: Acceptance of regulatory submission in US for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Dec 2023: Data readout from DREAMM-8 trial in combination with pomalidomide and dexamethasone for 2L+ multiple myeloma Jul 2023 - Sep 2023 : Regulatory approval for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Sep 2023 : Regulatory approval for 2L+ multiple myeloma (based on DREAMM-8 trial) Jan 2021 - Dec 2021 : Initiation of DREAMM-10 trial for 1L transplant ineligible multiple myeloma in combination with novel agent Dec 2020 - Dec 2020 : Data from DREAMM-8 trial for multiple myeloma at ASH 2020 More	Recruiting	3	357	Europe, Japan, US, RoW	Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib	GlaxoSmithKline	Multiple Myeloma	01/24	05/29
DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma Jul 2024 - Dec 2024 : Data for RRMM	Active, not recruiting	2	177	Europe, Canada, US, RoW	Belantamab mafodotin	GlaxoSmithKline	Multiple Myeloma	08/24	02/25
NCT04278924 / 2019-004103-12: A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia	Completed	2	41	Europe, Japan, US, RoW	Placebo, TAK-079	Takeda	Primary Immune Thrombocytopenia	04/24	04/24
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis First patient dosed as a monotherapy in patients with 2L myelofibrosis Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis	Active, not recruiting	2	112	Europe, US, RoW	Selinexor, Physician's Choice Treatment	Karyopharm Therapeutics Inc	Myelofibrosis	01/25	01/25
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma	Completed	1/2	272	Europe, Canada, Japan, US, RoW	Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone	Takeda, Takeda Development Center Americas, Inc.	Multiple Myeloma	07/24	11/24
Katsanos, Konstantinos
No trials found